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Abstract
Introduction:  Endovascular abdominal aortic aneurysm repair is a life-saving intervention.
Nevertheless, complications have a major impact. We review the evidence from case reports for
risk factors of complications after endovascular abdominal aortic aneurysm repair.
Case presentation: We selected case reports from PubMed reporting original data on adverse
events after endovascular abdominal aortic aneurysm repair. Extracted risk factors were: age, sex,
aneurysm diameter, comorbidities, re-interventions, at least one follow-up visit being missed or
refusal of a re-intervention by the patient. Extracted outcomes were: death, rupture and (non-
)device-related complications.
In total 113 relevant articles were selected. These reported on 173 patients. A fatal outcome was
reported in 15% (N = 26) of which 50% came after an aneurysm rupture (N = 13). Non-fatal
aneurysm rupture occurred in 15% (N = 25). Endoleaks were reported in 52% of the patients (N =
90). In half of the patients with a rupture no prior endoleak was discovered during follow-up. In
83% of the patients one or more re-interventions were performed (N = 143). Mortality was higher
among women (risk ratio 2.9; 95% confidence interval 1.4 to 6.0), while the presence of
comorbidities was strongly associated with both ruptures (risk ratio 1.6; 95% confidence interval
0.9 to 2.9) and mortality (risk ratio 2.1; 95% confidence interval 1.0 to 4.7). Missing one or more
follow-up visits (≥1) or refusal of a re-intervention by the patient was strongly related to both
ruptures (risk ratio 4.7; 95% confidence interval 3.1 to 7.0) and mortality (risk ratio 3.8; 95%
confidence interval 1.7 to 8.3).
Conclusion: Female gender, the presence of comorbidities and at least one follow-up visit being
missed or refusal of a re-intervention by the patient appear to increase the risk for mortality after
endovascular abdominal aortic aneurysm repair. Larger aneurysm diameter, higher age and
multimorbidity at the time of surgery appear to increase the risk for rupture and other
complications after endovascular abdominal aortic aneurysm repair. These risk factors deserve
further attention in future studies.
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Introduction
Up to the last decade of the last century, open surgery was
the procedure of choice for abdominal aortic aneurysm
(AAA) repair. Today, however, a minimally invasive
endovascular procedure can be performed. Randomised
trials show that short-term survival is better after endovas-
cular abdominal aortic aneurysm repair (EVAR) than after
open AAA repair [1,2]. After 2 years of follow-up, the total
cumulative mortality in both groups is the same owing to
excess mortality in the endovascularly treated group [3,4].
Randomised trials provide generally good evidence of
causal effects of treatments, but the quality of evidence on
the risk of adverse events is less satisfactory. This may
often be the result of the selection of relatively healthy
patients and the limited length of follow-up.
Extensive and long-lasting follow-up screening is gener-
ally required after EVAR. These extensive follow-up exam-
inations may be a considerable burden for patients and
health care providers, but they are necessary for early
detection of postoperative complications [5,6]. Most
complications are graft related and include graft migra-
tion, endoleak, graft thrombosis and AAA rupture. Rehos-
pitalisation and re-intervention is necessary to treat many
of these complications. Two European registries have
reported a 3% risk of complications per year and a 10%
risk of re-interventions per year [7-9]. Counterintuitively,
registry data have shown that the risk of complications is
significantly lower in patients who missed at least one fol-
low-up visit compared with patients who attended all vis-
its [10]. It is likely that these results are the consequence
of selective surveillance in patients who are at increased
risk for complications. Currently, no agreement exists on
the optimal post-procedural surveillance regimen and the
impact of frequent follow-up visits on the risk of compli-
cations after EVAR [11-13].
Evidence regarding the risk of complications after EVAR
and predictors of these risks is lacking. Better insight into
risk factors for complications after EVAR may lead to
improvements in the efficiency of follow-up and patient
selection. The aim of this study is to provide more insight
into determinants of prognosis after EVAR by unique
means: a meta-analysis of case reports.
Data sources and study selection
The PubMed-Medline database was searched for case
reports published up to January 2006. The following
search string was used: ((('aorta' and 'aneurysm') or ('Aor-
tic Aneurysms, Abdominal' [MESH])) and 'endovascular'
and 'Case Reports' [pt]).
Titles, abstracts and full-text publications were obtained
and screened for original data on adverse events after
EVAR. Exclusion criteria were: 1, non-abdominal aneu-
rysm; 2, inflammatory abdominal aortic aneurysm; 3,
AAA rupture treatment. No language restrictions were
applied. Full-text versions were obtained of all remaining
articles.
Data extraction and quality assessment
The following data about risk factors were extracted from
the selected articles: age, gender, AAA diameter, comor-
bidities, endograft brand and type, one or more follow-up
visits being missed and refusal of a re-intervention by the
patient. The following data about clinical endpoints were
documented: death, device-related complications and
non-device-related complications. When a patient experi-
enced more than one complication, all complications
were documented. Device-related complications
included: AAA rupture, endoleak types I, II, III, IV and V
(endotension), graft infection, graft migration, graft
thrombosis, graft kinking, stent wire fracture and techni-
cal mal-deployment. Non-device-related complications
included cardiac, pulmonary and renal complications, fis-
tula, ischaemia, multiple organ failure and other non-
device-related complications.
Data synthesis and analysis
Risk factors were associated with clinical endpoints by
cross-tabulation. Risk ratios (RRs) and 95% confidence
intervals (CIs) were calculated using Episheet [14]. A P
value of less than 0.05 was considered significant.
Case presentation
The Medline search strategy resulted in a total of 353 case
reports. After excluding articles on the basis of the inclu-
sion and exclusion criteria, 113 case reports remained
which reported original data about 173 patients who had
undergone endovascular AAA repair.
Table 1 shows baseline characteristics of the study popu-
lation. Eighty percent of the patients were male (N = 138),
14% female (N = 24) and no data were available about
gender in 6.3% of the patients (N = 11). The mean AAA
diameter prior to device implantation was 60 mm (stand-
ard deviation 11; range 42 to 95). The AAA diameter was
smaller than 5.5 cm in 25% of all patients (N = 43). The
mean age was 73 years (range: 52 years to 93 years).
The median time from device implantation to death, rup-
ture or other complications was 8.5 months with a range
of 0 to 85 months. Table 2 provides an overview of the
reported complications in our study population. A fatal
outcome was reported for 15% of all patients (N = 26).
AAA rupture caused death in 50% of these patients (N =
13). Death was directly or indirectly related to EVAR in the
other 50% (N = 13), which mostly occurred after compli-
cations of conversion to open AAA repair or aortoduode-
nal fistula.Journal of Medical Case Reports 2008, 2:317 http://www.jmedicalcasereports.com/content/2/1/317
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AAA rupture occurred in 22% of all patients (N = 38). The
AAA rupture was fatal in 34% of these patients (N = 13)
and non-fatal in 66% of these patients (N = 25). Interest-
ingly, in 50% of the patients with an AAA rupture (N =
19), no prior endoleak was detected during regular post-
operative follow-up. Other complications that were
reported for patients in the total study population
included endoleaks in 52%, graft thrombosis in 11% and
graft infections in 3%. Technical device-related complica-
tions, including mal-deployment of the graft, graft migra-
tion, graft kinking and stent wire fracture, occurred in
35% of all patients (N = 61). Non-device-related compli-
cations occurred in 42% of all patients (N = 73).
One or more re-interventions were performed in 83% of
all patients. The main indications for re-intervention
included embolisation, conversion to open AAA repair,
clipping of arteries, operative exploration, thrombectomy
and thrombolysis. Table 3 shows the calculated RRs and
95% CIs of associations of clinically relevant factors with
subsequent mortality and rupture after EVAR. The risk of
mortality was higher for female patients than for male
Table 1: Characteristics of the study population
N or mean ± standard deviation Percentage or range
Gender
Male 138 80%
Female 24 14%
Unspecified 11 6%
Age at operation (years) 72.47 ± 7.62 (52 to 93)
50 to 59 years 74 %
60 to 69 years 41 24%
70 to 79 years 83 48%
80 to 89 years 26 15%
90 to 99 years 11 %
Unspecified 15 9%
Comorbidities
Diabetes 53 %
Smoking 53 %
Hypertension 21 12%
Hypercholesterolaemia 63 %
Cardiac status 25 14%
Obesity 74 %
Stroke 53 %
Pulmonary status 21 12%
Renal status 10 6%
Other* 23 13%
Peripheral vascular disease 74 %
Carotid disease 11 %
Number of comorbidities
0 or unspecified 114 66%
1 or 2 26 15%
≥3 33 19%
AAA diameter 59.78 ± 11.04 42 to 95
Incomplete follow-up adherence† 85 %
Time interval between EVAR and complication (months) 13.73 ± 16.11 0 to 85
Perioperative, up to 24 hours 31 18%
Initial, up to 30 days post-operative 28 16%
Short term, 30 days to 6 months 15 9%
Early mid-term, 6 months to 2 1/2 years 62 36%
Late mid-term, 2 1/2 years to 5 years 23 13%
Long term, > 5 years 42 %
Unspecified 10 6%
*Other comorbidities that were described in the case reports included: active hepatitis C, alcohol abuse, arteriocaval fistula, bilateral gunshot injury, 
chemoradiation, cholangitis, Crohn's disease, factor VII deficiency, degenerative joint disease of lumbar spine, hemicolectomy, 'hostile' abdomen, 
hyperthyreoidectomy, hypoplastic marrow, liver cirrhosis, lymphoma, multiple gastrointestinal and urogenital operations, non-Hodgkin's lymphoma, 
pancreatoduodenectomy, pancytopenia, polycystic kidney disease, prostate cancer, rectal cancer, sigmoid resection and renal transplantation. 
†'Incomplete follow-up adherence' is defined by the patient missing one or more follow-up visits or refusing a re-intervention. AAA, abdominal 
aortic aneurysm; EVAR, endovascular abdominal aortic aneurysm repair; SD, standard deviation.Journal of Medical Case Reports 2008, 2:317 http://www.jmedicalcasereports.com/content/2/1/317
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patients (RR 2.9, 95% CI 1.4 to 6.0). A patient missing
one or more follow-up visits or refusing a re-intervention
appeared to increase the risk of both rupture and mortal-
ity (RR 4.7, 95% CI 3.1 to 7.0; and RR 3.8, 95% CI 1.7 to
8.3, respectively). The presence of at least three comorbid-
ities was also significantly associated with rupture and
mortality (RR 1.6, 95% CI 0.9 to 2.9; and RR 2.1, 95% CI
1.0 to 4.7, respectively). Larger AAA diameter and higher
age appeared to be associated with increased AAA rupture
risks, although none of the associations reached signifi-
cance.
Discussion
Female gender, comorbidities, missing one or more fol-
low-up visits or refusal of a re-intervention by the patient
appear to significantly increase the risk for mortality after
EVAR. No prior endoleak was discovered during follow-
up in 50% of the patients with an AAA rupture after EVAR.
Larger aneurysm diameter, higher age and comorbidities
may also increase the risk for AAA rupture after EVAR,
although these associations could not be established sig-
nificantly.
To the best of the authors' knowledge this is the first meta-
analysis of case reports. Case reports do not provide
strong causal evidence because they report only a small
number of patients. Case reports can provide relevant
information, notably on long-term complications in the
realm of patients actually seen and treated in daily prac-
tice. Although they could be emphasising the bizarre [15],
case reports are considered an important cornerstone for
medical progress. This type of article can help to detect
specific patterns of patient outcomes, particularly with
regard to clinically important and rare adverse events and
complications [16]. Case reports may therefore offer valu-
able information about the mechanisms of the develop-
ment of complications.
The aim of our study was to review which patient, disease
or procedural characteristics predict complications after
EVAR. The selection of case reports about patients with
complications after EVAR may have resulted in a cohort of
patients who are at high risk for complications, irrespec-
tive of the device or the procedure. Therefore, one may
question whether these extraordinary patients may have
brought the complications to the device or procedure.
Although patients who were included in this study may
represent the odd and extraordinary cases, they clearly are
patients who are seen in practice. For ethical considera-
tions and reasons of efficiency, these odd and extraordi-
nary cases are generally excluded from randomised trials
and cohort studies. The risk factors derived from the pre-
sented cohort of case reports are similar to those reported
in prognostic cohort studies. Hence, our results contribute
to the robustness of the reported predictors.
Unfortunately, the documentation of clinical data was not
performed according to a standardised protocol [17] in
many case reports. As data in our study were limited to
data that were presented in the selected case reports, a
considerable amount of data was missing. The percent-
ages of missing data in our study were 6.3% for gender,
8.7% for age, 5.8% for the time interval between EVAR
and complication, and 17% for initial AAA diameters.
Univariate analyses were performed to calculate associa-
tions between putative risk factors and subsequent clinical
outcomes for different subgroups on the basis of the avail-
able data and also for the group of patients with missing
and/or unspecified data. Comorbidities were described in
34% of all patients. From our point of view, this percent-
age can best be regarded as the minimum value of the
number of patients with comorbidities, because under-
reporting of comorbidities is likely in the other 66%.
Missing data is a disadvantage which is inevitably linked
Table 2: Complications after endovascular abdominal aortic 
aneurysm repair
Complication N Percentage
Device related
Endoleak 98 57%
Type I 25 14%
Type II 26 15%
Type III 12 7%
Type IV 0 0%
Type V/endotension 5 3%
Unspecified 30 17%
Kinking of stent graft 9 5%
Thrombosis of stent graft 19 11%
Graft migration 26 15%
Stent wire fracture 12 7%
Graft infection 5 3%
Technical deployment problems 13 8%
Non-device related
Multiple organ failure 8 5%
Cardiac 7 4%
Pulmonary 8 5%
Renal 8 5%
Fistula 11 6%
Ischaemic, embolic 25 14%
Other* 6 3%
Secondary intervention 144 83%
Open conversion 57 33%
AAA rupture 38 22%
Fatal course 26 15%
*Other complications that were described in the case reports 
included: heparin-induced thrombocytopenia, metal-induced 
pruriginous dermatitis, peri-aortitis with ureteral obstruction, upper 
gastric intestinal bleed, sloughing of scrotal skin and impotence. AAA, 
abdominal aortic aneurysm.Journal of Medical Case Reports 2008, 2:317 http://www.jmedicalcasereports.com/content/2/1/317
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with the unique approach, and should be regarded care-
fully when interpreting the results.
Several studies have compared mortality and morbidity
risks in men and women after EVAR. Two national data-
base studies in the US have shown that mortality after
EVAR is significantly 2.0 to 2.5 times higher in women
than in men [18,19]. The EUROSTAR study indicated that
female gender was a significant risk factor for endoleak
[20]. In addition to significantly reduced sizes of iliacal
arteries, women are more likely to have a shorter, more
dilated and more angulated proximal aortic neck, which
may lead to proximal endoleak and graft migration [21].
Female patients also have a higher risk of abortion of the
initial EVAR procedure and mal-deployment of the
endograft [22]. Wolf et al. showed that women had signif-
icantly more intra-operative complications compared
with men. They hypothesised that this was related to dif-
ferences in arterial access [23]. Nordness et al. showed
that women were more likely to have significant arterial
dissections during EVAR. One-month mortality risks were
12% in female and 0% in male patients (P = 0.02). One-
month complication risks were 41% in women and 15%
in men (P = 0.02) [24]. Ouriel et al. found no differences
between men and women in perioperative and mid-term
mortality. However, they demonstrated a higher risk for
graft-limb occlusions in women than in men [25].
The impact of comorbidities on the risk of mortality after
EVAR has been described by several authors. Azizzadeh et
al. showed that patients with a low glomerular filtration
rate (GFR) faired significantly worse than patients with a
better GFR [26]. Biancari et al. showed that survival was
significantly different among tertiles of the Glasgow Aneu-
rysm Score, which is a tool for measuring the fitness of the
patient for surgery (P < 0.001). Patients with a high score
and extensive comorbidities had a significantly lower 5-
year survival rate than the other patients [27]. Chaikof et
al. categorised patients into a high-risk group (N = 123)
and a low-risk group (N = 113) according to the clinical
condition of the patient. The 2-year survival was 73.5%
for high-risk patients and 85.8% for low-risk patients (P =
Table 3: Risk ratios and 95% confidence intervals of associations of clinically relevant factors with subsequent mortality and rupture 
after endovascular abdominal aortic aneurysm repair
Death or rupture Rupture Death
N total N events Risk RR (95%CI) N events Risk RR (95%CI) N events Risk RR (95%CI)
Gender
Male 138 36 0.26 - 29 0.21 - 16 0.12 -
Female 24 11 0.46 1.8 (1.0;2.9)* 6 0.25 1.2 (0.6;2.6) 8 0.33 2.9 (1.4;6.0)*
Unspecified 11 4 0.36 1.4 (0.6;3.2) 3 0.27 1.3 (0.5;3.6) 2 0.18 1.6 (0.4;6.0)
Age at operation 
50 to 59 years 7 2 0.29 - 1 0.14 - 2 0.29 -
60 to 69 years 41 10 0.24 0.9 (0.2;3.0) 9 0.22 1.5 (0.2;10) 3 0.07 0.3 (0.1;1.3)
70 to 79 years 83 24 0.29 1.0 (0.3;3.4) 15 0.18 1.3 (0.2;8.2) 12 0.14 0.5 (0.1;1.8)
80 to 89 years 26 10 0.38 1.3 (0.4;4.8) 9 0.35 2.4 (0.4;16) 6 0.23 0.8 (0.2;3.2)
90 to 99 years 1 1 1.00 3.5 (1.1;11)* 1 1.00 7.0 (1.1;43)* 1 1.00 3.5 (1.1;11)
Unspecified 15 4 0.27 0.9 (0.2;3.9) 3 0.20 1.4 (0.2;11) 2 0.13 0.5 (0.1;2.7)
N comorbidities
0 or unspecified 114 27 0.24 - 24 0.21 - 13 0.11 -
1 or 2 26 8 0.31 1.3 (0.7;2.5) 3 0.12 0.5 (0.2;1.7) 5 0.19 1.7 (0.7;4.3)
≥3 33 16 0.48 2.0 (1.3;3.3)* 11 0.33 1.6 (0.9;2.9) 8 0.24 2.1 (1.0;4.7)*
AAA diameter
4 0  t o  4 9  m m 1 5 50 . 3 3 - 30 . 2 0 - 30 . 2 0 -
50 to 59 mm 67 19 0.28 0.9 (0.4;1.9) 13 0.19 1.0 (0.3;3.0) 11 0.16 0.8 (0.3;2.6)
60 to 69 mm 36 10 0.28 0.8 (0.3;2.0) 8 0.22 1.1 (0.3;3.6) 5 0.14 0.7 (0.2;2.5)
70 to 79 mm 14 8 0.57 1.7 (0.7;4.0) 7 0.50 2.5 (0.8;7.8) 2 0.14 0.7 (0.1;3.7)
> 80 mm 11 4 0.36 1.1 (0.4;3.1) 3 0.27 1.4 (0.3;5.5) 3 0.27 1.4 (0.3;5.5)
Unspecified 30 5 0.17 0.5 (0.2;1.5) 4 0.13 0.7 (0.2;2.6) 2 0.07 0.3 (0.1;1.8)
AAA, abdominal aortic aneurysm; CI, confidence interval; RR, risk ratio. *P value less than 0.05.Journal of Medical Case Reports 2008, 2:317 http://www.jmedicalcasereports.com/content/2/1/317
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0.035 [28]. Riambau et al. showed that patients with a
poor medical condition had a significantly lower 1-year
survival after EVAR compared with relatively fit patients:
83% versus 93% (P < 0.001). Diabetes mellitus appears to
influence mortality considerably [29]. Zannetti et al.
divided patients in subgroups according to the American
Society for Anesthesiology (ASA) classification. Cumula-
tive survival was 89% in the ASA < IV and 76% in the ASA
IV group (P = 0.004) after 3 years of follow-up [30]. These
reports, in combination with our results, underscore the
impact of comorbidities on mortality and morbidity after
EVAR.
Missing one or more follow-up visit appeared to increase
the risk of complications in our study. As far as we know,
this has never been described before. The EUROSTAR
study showed counter-intuitively that the risk of compli-
cations was significantly higher in patients with a perfect
follow-up adherence. Compliance with follow-up screen-
ing in their study appeared to be biased, however, because
high-risk patients, including smokers, patients with
hyperlipidaemia, and patients who were unfit for open
surgery or general anaesthesia had the best follow-up
adherence [10]. Therefore, extensive follow-up screening
and re-interventions are still required after EVAR.
Conclusion
Although a meta-analysis of case reports has some clear
methodological drawbacks, it offers unique opportuni-
ties. The risk factors for complications after endovascular
AAA repair that are presented in this document are similar
to those that are presented in prognostic cohort studies.
Female gender and the presence of comorbidities appear
to increase the risk of mortality after EVAR. Larger AAA
diameter, higher age and multimorbidity at the time of
surgery increase the risk for rupture and other complica-
tions following EVAR. These risk factors deserve attention
in future well-designed follow-up studies.
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